about
Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledgeThe advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational SummitCreating a transatlantic research enterprise for preventing Alzheimer's disease2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease.Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimer's Disease.Diagnosis of Alzheimer's disease: two-decades of progress.Barriers to drug discovery and development for Alzheimer disease.Models and modeling systems in Alzheimer disease drug discovery.Developing a national strategy to prevent dementia: Leon Thal Symposium 2009.Massachusetts Alzheimer's Disease Research Center: progress and challenges.Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium.Methodological issues in primary prevention trials for neurodegenerative dementia.A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.Diagnosis of Alzheimer's disease: two decades of progress.Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned?Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development.Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria.Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.A chapter in the development of Alzheimer's disease research: a case study of public policies on the development and funding of research programs.Politics of science: Progress toward prevention of the dementia-Alzheimer's syndrome.The draft "National Plan" to address Alzheimer's disease - National Alzheimer's Project Act (NAPA).Revisiting the cholinergic hypothesis in Alzheimer's disease: Emerging evidence from translational and clinical research.Big data, aging, and dementia: pathways for international harmonization on data sharing.Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery.The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions.Zenith Award Program of the Alzheimer's Association.Robert Katzman: the man and his legacy.Leon Joel Thal, MD, 1944-2007: honoring his scientific legacy.History of Alzheimer's research: the politics of science in building a national program of research.Revised criteria for diagnosis of Alzheimer's disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines for Alzheimer's disease.Military risk factors for Alzheimer's dementia and neurodegenerative disease.Perspective on the Alzheimer's disease neuroimaging initiative: progress report and future plans.Zeroing out preventable disability: Daring to dream the impossible dream for dementia care: Recommendations for a national plan to advance dementia care and maximize functioning.Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010.Healthy aging and preclinical dementia: the United States-Israel Longitudinal Database project.The Special Topics Section of Alzheimer's & Dementia.
P50
Q26745466-30703662-B68D-435F-8616-E57B5E313A87Q28485924-F886590B-888F-4C6C-BFD2-446FA4E4AF60Q28709591-15EAF1FE-F30A-4AEE-B36A-CF9E4CBB6FF9Q28731473-8AE1439A-3F4E-4DCB-8192-A7250D32AA32Q30303063-73EF34B3-4A4F-4E1E-AA10-031DD39289CAQ30316312-A96F3ABC-9735-4D13-A932-7041EB677A7CQ31055023-5B48FB70-0776-4E30-8783-8464145AF365Q34691815-2378C900-7639-4A41-A4C8-46D68CC5AA52Q34691822-1D7CB61F-F7CB-4D39-BB71-B4C5776ACD5BQ34984743-D93F041A-2F2E-491C-9294-0E9EC7FE25AEQ36304325-7F43A4E1-C785-4DA4-BE91-745AA52E86BDQ36885357-792FE670-E56C-42DD-845C-16C3035F521AQ36893856-9536FB36-CAE7-4E0E-BD6D-F55885CCE01CQ37394535-67EBC034-5821-4A89-8318-81F12C8955F6Q37425789-8DF40ED7-66D1-4293-ACC8-D7A8DDD1019FQ37549209-2E23A502-EECA-4A27-8399-CD71C4692776Q37549261-25C306CA-BEDF-41B3-A82A-2D462259C556Q38022911-035DFD52-02FF-4B75-9710-6FC6C3D18110Q38050217-6752AFE0-3248-4EB0-BDEF-B34ADF786104Q38134442-B89DDD38-84BE-49F2-A433-6AB6550FC02DQ38166086-034A1C0B-00DE-46B4-929F-F3E601755697Q38447617-11B20888-B26E-4570-8658-C455929E5212Q38520798-340D4E84-AF3F-4CB3-B571-996970DF5E03Q39623102-2AA2EB20-C63A-40E6-8D97-85AA0ADECC15Q42516743-D4CEBC0B-27CD-4990-AC5D-139A7C9B32CAQ42623294-28ECDD1D-6A8C-4BE1-9C35-937AA5F55656Q44595079-24615370-DB4C-4843-8804-02BFBC747888Q47549851-3BB2F5EA-8E05-48B2-A2AC-B4BEA90BB88CQ47549851-C4C4C2F4-3735-4756-92EA-F24A894438FCQ47549851-F91DEDFD-ED14-4977-8331-2F8B6E4C086CQ47881266-18475620-5BF5-4963-B980-A6E59FFDB9ADQ48327819-5A2791CA-5303-417E-89EB-42E9F6DFB15CQ48503594-1CEC091C-DEBB-4CF7-B6A2-47E7DF798A13Q48513908-F786F4F4-59DF-4755-8EB8-0A601B785435Q48588504-1FDC0D01-0DFD-447D-BCB8-6908384DB95DQ48668916-0F5B01F2-B371-4C2C-A571-F41BFE1F484FQ48718362-8B0091B1-4385-444F-8A17-E890F1D6D6DCQ48819404-1D0C889B-67B5-428F-8328-20F6602B06C2Q49957376-71A38A7D-9DD5-462C-91CA-5260B783F4A8Q51016539-C3E67716-3C78-4920-8F11-1A305BA591A4
P50
name
Zaven S Khachaturian
@en
type
label
Zaven S Khachaturian
@en
prefLabel
Zaven S Khachaturian
@en